[KSCI] Korea Science Citation Index Service

http://dx.doi.org/10.4062/biomolther.2008.16.2.141

The Change of Bone Mineral Density by Bisphosphonates Therapy with Calcium-Antagonists in Osteoporosis

Kim, Soon-Joo (College of Pharmacy and Research Institute of Pharmaceutical Science, Sookmyung Women's University)
La, Hyen-Oh (Pharmacology, College of Medicine, The Catholic University)
Kang, Young-Sook (College of Pharmacy and Research Institute of Pharmaceutical Science, Sookmyung Women's University)

Publication Information

Biomolecules & Therapeutics / v.16, no.2, 2008 , pp. 141-146 More about this Journal

Abstract

Imbalance in calcium and phosphorous metabolism due to aging or menopause leads to osteoporosis. In contrast to patients with normal blood pressure, hypertensive patients have a higher loss of calcium in the urine with its attendant risk of osteoporosis. The high blood pressure is associated with the risk of bone loss and abnormalities in calcium metabolism leading to calcium loss. So we retrospectively investigated the changes of bone mineral density (BMD) which drugs can have clinical influences over osteoporosis treatments of patients with calcium-antagonists as common antihypertensive drugs and with bisphosphonates which causes a most effective inhibition of osteoclasts resorption. As a result over 70 years of age group and within bisphosphonates group, alendronate 70 mg once-weekly group showed significant increase of BMD in lumbar area. Combination group of cilnidipine and $maxmarvil^{(R)}$ showed very significant decrease of BMD. In conclusion, it is desirable that combination therapy with calcium-antagonists is used carefully in the treatment of osteoporosis with high blood pressure.

Keywords

bone mineral density; bisphosphonates; alendronate; calcium-antagonists; cilnidipine;

Citations & Related Records

Times Cited By Web Of Science : 0 (Related Records In Web of Science)
Times Cited By SCOPUS : 0

Reference

1	Bone, H.G., Hosking, D., Devogelaer, J.P., Tucci, J.R., Emkey, R.D., Tonino, R.P., Rodrigue-Portales, J.A., Downs, R.W., Gupta, J., Santora, A.C., and Liberman U.A. (2004). Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl Med., 350, 1189-1899 DOI ScienceOn
2	Schnitzer, T., Bone, H.G., Crepaldi, G., Adami, S., McClung, M., Kiel, D., Felsenberg, D., Recker, R.R., Tonino, R.P., Roux, C., Pinchera, A., Foldes, A.J., Greenspan, S.L., Levine, M.A., Emkey, R., Santora, A.C. 2nd., Kaur, A., Thompson, D.E., Yates, J., and Orloff, J.J. (2000), Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis., Aging(Milano). 12(1), 1-12
3	Jiliang, L.I., Randall, L.D., David, B.B., and Charles, H.T. (2002). L-type calcium channels mediate mechanically induced bone formation in vivo. J Bone Mine. 17(10), 1795-1800 DOI ScienceOn
4	Kim, B.C., Kim, D.H., and Hur, M. (1988). A study of symptomatology, lipid change and hormonal change in the menopausal women. Korean J Obstet Gynecol. 31(6), 784-794
5	Liberman, U.A., Weiss, S.R., Broll, J., Minne, H.W., Quan, H., Bell, N.H., Rodriguez-Portales, J., Downs, R.W. Jr., Dequeker, J., and Favus, M. (1995). Effect of oral alendronate on BMD and the incidence of fractures in postmenopausal osteoporosis. N Engl Med., 333(22), 1437-1443 DOI ScienceOn
6	Luckey, M., Kagan, R., Greenspan, S., Bone, H., Kiel, R.D., Simon, J., Sackarowitz, J., Palmisano, J., Chen, E., Petruschke, R.A., and de Papp, A.E. (2004). Once-weekly alendronate 70 mg and raloxifene 60 mg daily in the treatment of postmenopausal osteoporosis. Menopause. 11(4), 405-415 DOI ScienceOn
7	Mori, Y., Mikala, G., Vardi, G., Kobayashi, T., Koch, S., Wakamori, M., and Schwartz A. (1996). Molecular pharmacology of voltage-dependent calcium channels. Jpn J Pharmacol. 72, 83-109 DOI
8	Rosen, C.J., Hochberg, M.C., Bonnick, S.L., McClung, M., Miller, P., Broy, S., Kagan, R., Chen, E., Sambrook, P.N., Geusens, P., Ribot, C., Solimano, J.A., Ferrer-Barriendos, J., Gaines, K., Verbruggen, N., and Melton M.E. (2004). Alendronate produces greater effects than raloxifen on bone density and bone turnover in postmenopausal women with low bone density: results EFFECT International, J Int Medicine. 255, 503-511 DOI ScienceOn
9	Reid, D.M., Hosking, D., Kendler, D., Brandi, M.L., Wark, J.D., Marques-Neto, J.F., Weryha, G., Vebruggen, N., Hutad, C.M., Mahlis, E.M., and Melton, M.E. (2008). A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24 month results from FACTS-International. Int J Clin Pract. 62(4), 575- 584 DOI ScienceOn
10	Reiner, B. and Bertha, F. (2003). Osteoporosis. Springer
11	Shun-ichi, H. and Gideon, A.R. (2003). Control of osteoblast function and regulation of bone mass., Nature. 423, 349-355 DOI ScienceOn
12	Takao, S. (1998). Current status of calcium-antagonists in Japan. Am J Cardio., 82(9B), 32R-34R
13	Zekai, H., Bunyamin, B., Yuksel, O., Elif, C., and Halis, S. (2008). Protective effects of amlodipine and lacidipine on ovariectomy- induced bone loss in rats. Eur J Pharmaco, 579, 241-245 DOI ScienceOn
14	Bone, H.G., Robert, W.D., Joseph, R.T., Steven, T.H., Robert, S.W., Angelo, A.L., Michael, R.M., Donald, B.K., Barry, J.G., Erika, H., and William J.P. (1997). Dose-response relationships for alendronate treatment in osteoporotic elderly women. J Clini Endocrinol Metab. 82(1), 265-274 DOI
15	Albers, M.M., Johnson, W.V., and Jackson, R.D. (1991). Chronic use of the calcium channel blocker nifedipine has no significant effect on bone metabolism in men. Bone. 12, 39-42 DOI ScienceOn
16	Gotoh, M., Mizuno, K., Ono, Y., and Takahashi, M. (2005). High blood pressure, bone-mineral loss and insulin resistance in women. Hypertens Res. 28(7), 565-570 DOI
17	Guggino, S.E., Wagner, J.A., Snowman, A.M., Hester, L.D., Sacktor, N., and Snyder, S.H. (1988). Phenylalkylamine-sensitive calcium channels in osteoblast-like osteosarcoma cells. J Biol Chem, 263, 10155-61
18	Nishiya, Y. and Sugimoto, S. (2001). Effects of various antihypertensive drugs on the function of osteoblast. Biol. Pharm. Bull. 24(6), 628-633 DOI ScienceOn
19	Nishiya, Y., Kosaka, N., Uchii, M., and Suginoto, S. (2002). A potent 1,4-dihydropyridine L-type calcium channel blocker, benidipine, promotes osteoblast differentiation. Calcif Tissue Int. 70, 30-39 DOI
20	Barry, E.L.R. (2000). Expression of mRNAs for the $\alpha$ 1 subunit of voltage-gated calcium channels in human osteoblast-like cell lines and in normal human osteobasts. Calcif Tissue Int. 66, 145-150 DOI
21	Cappuccio, F.P., Meilahn, E., Zmuda, J.M., and Cauley, J.A. (1999). High blood pressure and bone-mineral loss in elderly white women: a prospective study. Study of osteoporotic fractures research group. Lancet. 354, 971-975 DOI ScienceOn
22	Caren, G.S. (2002). Bisphosphonates and Osteoporosis., N Eng J Med. 346(9) 642 DOI ScienceOn
23	Duriez, J., Flautre, B., Blary, C., and Hardouin, P. (1993). Effects of the calcium channel blocker nifedipine on epiphyseal growth plate and bone turnover: a study in rabbit. Calcif Tissue Int. 52, 120-124 DOI
24	Eva, S., Diane, M.C., Mohammed, P.A., and Donald, B.K. (2001). No effect of verapamil on the local bone response to in vivo mechanical loading. J Orth R. 19, 328-336 DOI ScienceOn